TOP1 and neoplasm: To further validate that CBX-12 selectively targeted tumor and not healthy tissues, we developed a FACS-based functional assay to monitor the effect of TOP1 inhibition on TOP1 protein levels in tumor tissue and bone marrow, based on previously published methodology (21).